Home
About
Overview
Sharing Data
ORCID
Help
History (19)
Darlington, Wendy
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
See All 19 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9.
View in:
PubMed
subject areas
Adult
Aged
Analysis of Variance
Antibodies, Monoclonal
Chi-Square Distribution
Crohn Disease
Cross-Over Studies
Double-Blind Method
Female
Gastrointestinal Agents
Humans
Infliximab
Infusions, Intravenous
Male
Middle Aged
Remission Induction
Treatment Outcome
authors with profiles
Stephen B. Hanauer